NCT05085834CompletedEarly phase 1
Zinc Effect on Inflammation and Cardiovascular Risk in HIV
Source: ClinicalTrials.gov · Last updated 12 Jun 2025
Brief summary (registry, in English)
To study the effect of short-term zinc supplementation on improving inflammation, metabolic, and cardiovascular risk among HIV infected patients on stable anti-retroviral therapy
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 95 (actual)
- First submitted
- 2 Jul 2019
- Start date
- Jan 2020
- Primary completion date
- Aug 2024
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Diseases
- HIV
- NCT number
- NCT05085834
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 95
- From Jan 2020 to the primary completion date, Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known cardiovascular disease
- Uncontrolled diabetes
Other
- Pregnancy/lactation
Who the study is looking for
- HIV-1 infection
- Documentation of an HIV-1 RNA level of ≤400 copies/mL in the last 4 months prior to study entry
- Male or Female age ≥18 years
- Zinc level ≤0.75 mg/L in the last 60 days
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospitals Cleveland Medical Center* Coordinator of this site? Confirm its status | Cleveland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.